News H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Market Closed - Nasdaq Copenhagen Other stock markets 15:59:54 17/05/2024 BST			5-day change	1st Jan Change
37.4 ^DKK	+0.43%		+8.16%	+14.16%

05-15	H LUNDBECK : Q1 beat adds momentum to the recent share price rally
05-15	Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H LUNDBECK : Q1 beat adds momentum to the recent share price rally	05-15
Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024	05-15
Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024	05-15	AQ
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024	05-15	CI
H LUNDBECK : Lundbeck is well-poised to sail through the transition period	05-13
Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck	05-13	AQ
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024	05-13	CI
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	04-09	MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	04-09	AQ
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	04-09	CI
Lundbeck : Articles of Association	04-02	PU
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	03-27	MT
Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia	03-27	AQ
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	03-27	CI
Lundbeck held its Annual General Meeting on 20 March 2024 at the company's registered office	03-20	AQ
H. Lundbeck A/S Announces Management Appointments	03-20	CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	03-20	CI
Transcript : H. Lundbeck A/S - Shareholder/Analyst Call	03-20
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug	03-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

H LUNDBECK : Q1 beat adds momentum to the recent share price rally

May 15, 2024 at 05:20 pm